HK1223281A1 - 使用携帶藥物的、雙特異性配體靶向的微細胞和干擾素-γ的聯合腫瘤治療 - Google Patents
使用携帶藥物的、雙特異性配體靶向的微細胞和干擾素-γ的聯合腫瘤治療Info
- Publication number
- HK1223281A1 HK1223281A1 HK16111560.9A HK16111560A HK1223281A1 HK 1223281 A1 HK1223281 A1 HK 1223281A1 HK 16111560 A HK16111560 A HK 16111560A HK 1223281 A1 HK1223281 A1 HK 1223281A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- interferon gamma
- tumor treatment
- drug loaded
- bispecific ligand
- targeted minicells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887258P | 2013-10-04 | 2013-10-04 | |
| PCT/IB2014/002824 WO2015049589A1 (en) | 2013-10-04 | 2014-10-03 | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1223281A1 true HK1223281A1 (zh) | 2017-07-28 |
Family
ID=52777107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16111560.9A HK1223281A1 (zh) | 2013-10-04 | 2016-10-04 | 使用携帶藥物的、雙特異性配體靶向的微細胞和干擾素-γ的聯合腫瘤治療 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9731011B2 (zh) |
| EP (1) | EP3052122A4 (zh) |
| JP (1) | JP6538031B2 (zh) |
| KR (1) | KR102433719B1 (zh) |
| CN (1) | CN105658233B (zh) |
| AP (1) | AP2016009153A0 (zh) |
| AU (1) | AU2014330895B2 (zh) |
| BR (1) | BR112016007100A2 (zh) |
| CA (1) | CA2926161C (zh) |
| EA (1) | EA032740B1 (zh) |
| HK (1) | HK1223281A1 (zh) |
| IL (1) | IL244851B (zh) |
| MX (1) | MX2016004285A (zh) |
| NZ (1) | NZ718148A (zh) |
| SG (1) | SG11201602429QA (zh) |
| TW (1) | TWI737576B (zh) |
| WO (1) | WO2015049589A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016004285A (es) * | 2013-10-04 | 2016-07-08 | Engeneic Molecular Delivery Pty Ltd | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. |
| WO2016051389A1 (en) * | 2014-10-03 | 2016-04-07 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| JP7213798B2 (ja) * | 2016-10-06 | 2023-01-27 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 核酸アジュバントを送達するための細菌ミニ細胞およびその使用方法 |
| JP7097438B2 (ja) | 2017-07-11 | 2022-07-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| AU2019301699B2 (en) | 2018-07-11 | 2023-11-02 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP2021532106A (ja) * | 2018-07-23 | 2021-11-25 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
| US20220105177A1 (en) * | 2019-01-04 | 2022-04-07 | Engenelc Molecular Delivery Pty Ltd | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
| WO2021191796A1 (en) * | 2020-03-24 | 2021-09-30 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing viral infections, including coronavirus infections, and methods of using the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2315067B (en) | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
| WO2000067776A1 (en) | 1999-05-11 | 2000-11-16 | Ortho-Mcneil Pharmaceuticals, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| WO2001036001A2 (en) * | 1999-11-12 | 2001-05-25 | Maxygen Holdings Ltd | Interferon gamma conjugates |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| DK1446489T3 (da) | 2001-10-15 | 2012-05-14 | Engeneic Molecular Delivery Pty Ltd | Intakte miniceller som vektorer for DNA-overførsel og genterapi in vitro og in vivo |
| EP1594547A2 (en) * | 2003-02-14 | 2005-11-16 | University Of South Florida Research Foundation, Inc. | Chitosan-microparticles for ifn gene delivery |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| JP4332558B2 (ja) * | 2003-12-09 | 2009-09-16 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニ細胞を介した非食作用性哺乳動物細胞への標的化遺伝子送達 |
| NZ549139A (en) | 2004-02-02 | 2009-11-27 | Engeneic Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| AU2005276145C1 (en) * | 2004-08-26 | 2011-01-06 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| CA2803995C (en) | 2004-08-26 | 2014-06-10 | Engeneic Molecular Delivery Pty Ltd. | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| CA2658058C (en) * | 2006-06-23 | 2016-08-23 | Engeneic Molecular Delivery Pty Ltd. | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| EP2532746A3 (en) | 2007-03-30 | 2013-08-14 | EnGeneIC Molecular Delivery Pty Ltd. | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| EP2646456B1 (en) | 2010-12-02 | 2015-01-21 | Nerviano Medical Sciences S.r.l. | Process for the preparation of morpholinyl anthracycline derivatives |
| ES2843402T3 (es) * | 2011-12-13 | 2021-07-16 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales |
| ES2828092T3 (es) * | 2012-10-02 | 2021-05-25 | Vaxiion Therapeutics Llc | Minicélulas inmunomoduladoras y métodos de uso |
| MX2016004285A (es) * | 2013-10-04 | 2016-07-08 | Engeneic Molecular Delivery Pty Ltd | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. |
-
2014
- 2014-10-03 MX MX2016004285A patent/MX2016004285A/es unknown
- 2014-10-03 JP JP2016519841A patent/JP6538031B2/ja active Active
- 2014-10-03 SG SG11201602429QA patent/SG11201602429QA/en unknown
- 2014-10-03 CA CA2926161A patent/CA2926161C/en active Active
- 2014-10-03 WO PCT/IB2014/002824 patent/WO2015049589A1/en active Application Filing
- 2014-10-03 AP AP2016009153A patent/AP2016009153A0/en unknown
- 2014-10-03 AU AU2014330895A patent/AU2014330895B2/en active Active
- 2014-10-03 TW TW103134613A patent/TWI737576B/zh active
- 2014-10-03 EP EP14851383.1A patent/EP3052122A4/en active Pending
- 2014-10-03 US US14/506,138 patent/US9731011B2/en active Active
- 2014-10-03 CN CN201480054853.1A patent/CN105658233B/zh active Active
- 2014-10-03 EA EA201690680A patent/EA032740B1/ru unknown
- 2014-10-03 NZ NZ718148A patent/NZ718148A/en unknown
- 2014-10-03 KR KR1020167010107A patent/KR102433719B1/ko active IP Right Grant
- 2014-10-03 BR BR112016007100A patent/BR112016007100A2/pt active Search and Examination
-
2016
- 2016-03-31 IL IL244851A patent/IL244851B/en active IP Right Grant
- 2016-10-04 HK HK16111560.9A patent/HK1223281A1/zh unknown
-
2017
- 2017-07-28 US US15/663,562 patent/US10500277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3052122A1 (en) | 2016-08-10 |
| US20150098897A1 (en) | 2015-04-09 |
| SG11201602429QA (en) | 2016-04-28 |
| MX2016004285A (es) | 2016-07-08 |
| EP3052122A4 (en) | 2017-05-17 |
| CN105658233A (zh) | 2016-06-08 |
| IL244851A0 (en) | 2016-05-31 |
| BR112016007100A2 (pt) | 2017-08-01 |
| JP6538031B2 (ja) | 2019-07-03 |
| TWI737576B (zh) | 2021-09-01 |
| JP2016532639A (ja) | 2016-10-20 |
| US20170326235A1 (en) | 2017-11-16 |
| IL244851B (en) | 2020-04-30 |
| US9731011B2 (en) | 2017-08-15 |
| WO2015049589A1 (en) | 2015-04-09 |
| CN105658233B (zh) | 2020-09-04 |
| CA2926161A1 (en) | 2015-04-09 |
| TW201601748A (zh) | 2016-01-16 |
| US10500277B2 (en) | 2019-12-10 |
| KR102433719B1 (ko) | 2022-08-17 |
| CA2926161C (en) | 2023-03-14 |
| EA201690680A1 (ru) | 2016-07-29 |
| EA032740B1 (ru) | 2019-07-31 |
| AU2014330895B2 (en) | 2019-08-15 |
| KR20160058885A (ko) | 2016-05-25 |
| AP2016009153A0 (en) | 2016-04-30 |
| NZ718148A (en) | 2022-02-25 |
| AU2014330895A1 (en) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223281A1 (zh) | 使用携帶藥物的、雙特異性配體靶向的微細胞和干擾素-γ的聯合腫瘤治療 | |
| HK1244493A1 (zh) | 使用凝固因子和多特異性抗體的聯合治療 | |
| ZA201505735B (en) | Cancer drug and uses | |
| HK1219631A1 (zh) | 自由劑量胰島素輸送系統和方法 | |
| HK1220916A1 (zh) | 治療癌症和預防癌症藥物抗性的方法 | |
| IL242881B (en) | A toxic substance for use in combination with radiation in cancer treatment | |
| HK1214533A1 (zh) | 治療癌症和預防癌症耐藥性的方法 | |
| HK1213180A1 (zh) | 治療和預防癌症藥物抗性的方法 | |
| ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
| HK1211235A1 (zh) | 治療癌症和預防藥物抗性的方法 | |
| SG11201701035SA (en) | Cancer diagnosis and therapy | |
| EP2944323A4 (en) | MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR | |
| HK1224233A1 (zh) | 注射器以及注射器組件 | |
| HK1245096A1 (zh) | 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療 | |
| HK1223267A1 (zh) | 藥劑供給體及藥劑供給單元 | |
| HK1215152A1 (zh) | 具有受控柔性的輸送導管 | |
| GB201511159D0 (en) | Controlled cell delivery vehicle and treatment of tumours | |
| EP2949326A4 (en) | MOLECULAR FIXED COMBINATION ACTIVE FOR TUMOR THERAPY AND PREVENTION | |
| HK1213475A1 (zh) | 用於癌症治療的 、卡培他濱和奧沙利鉑的組合 | |
| GB201322869D0 (en) | Therapeutic agents and delivery with microspheres | |
| GB201309498D0 (en) | Novel diagnosis and therapy | |
| EP3043721A4 (en) | PHARMACOLOGICAL DELIVERY SYSTEMS AND ASSOCIATED METHODS | |
| GB201312129D0 (en) | Drug combination and its use in therapy | |
| GB201312131D0 (en) | Drug combination and its use in therapy | |
| GB201312128D0 (en) | Drug combination and its use in therapy |